Cipla Ltd
- All
- News
- Videos
-
Cipla Recalls 6 Batches Of Bronchospasm Treatment Inhalation Aerosol In US
Pharmaceutical firm Cipla Ltd on Friday said it is voluntarily recalling six batches of Albuterol Sulfate inhalation aerosol in the US market due to container defect.
-
Cipla To Make, Sell US's Eli Lilly's Baricitinib Drug For Covid Treatment
Indian drugmaker Cipla Ltd said on Monday it has entered into a licensing agreement with U.S. company Eli Lilly and Co to make and sell Lilly's arthritis drug baricitinib for the treatment of COVID-19 patients.
-
Merck Taps 5 Indian Drugmakers To Expand Covid Drug Production
Merck & Co Inc said on Tuesday it had partnered with five Indian generic drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd, to expand production and access to its experimental COVID-19 drug.
-
Cipla Doubles Remdesivir Production In India For "Unprecedented" Demand
India's Cipla Ltd has doubled production of COVID-19 medication remdesivir to help meet "unprecedented demand" as the country battles a massive second wave of infections, the drugmaker said on Tuesday.
-
Indian Demand For COVID-19 Drug Remdesivir Rising Sharply: Cipla
Demand for COVID-19 antiviral drug remdesivir is rising sharply in India, a top executive at drugmaker Cipla Ltd said on Monday, even as experts remain divided over its effectiveness.
-
Cipla Set To Undercut Rivals With Generic Remdesivir: Sources
Indian drugmaker Cipla Ltd has priced its generic version of Remdesivir, Cipremi, at 4,000 rupees ($53.34) per 100 mg vial, according to several sources, making it among the lowest priced versions of the COVID-19 treatment available so far globally.
-
These Two Stocks To Be Added Into Sensex
Drugmakers Lupin Ltd and Cipla Ltd will make way for the two banks, according to a statement from Asia Index Pvt Ltd.
-
Cipla Recalls 6 Batches Of Bronchospasm Treatment Inhalation Aerosol In US
Pharmaceutical firm Cipla Ltd on Friday said it is voluntarily recalling six batches of Albuterol Sulfate inhalation aerosol in the US market due to container defect.
-
Cipla To Make, Sell US's Eli Lilly's Baricitinib Drug For Covid Treatment
Indian drugmaker Cipla Ltd said on Monday it has entered into a licensing agreement with U.S. company Eli Lilly and Co to make and sell Lilly's arthritis drug baricitinib for the treatment of COVID-19 patients.
-
Merck Taps 5 Indian Drugmakers To Expand Covid Drug Production
Merck & Co Inc said on Tuesday it had partnered with five Indian generic drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd, to expand production and access to its experimental COVID-19 drug.
-
Cipla Doubles Remdesivir Production In India For "Unprecedented" Demand
India's Cipla Ltd has doubled production of COVID-19 medication remdesivir to help meet "unprecedented demand" as the country battles a massive second wave of infections, the drugmaker said on Tuesday.
-
Indian Demand For COVID-19 Drug Remdesivir Rising Sharply: Cipla
Demand for COVID-19 antiviral drug remdesivir is rising sharply in India, a top executive at drugmaker Cipla Ltd said on Monday, even as experts remain divided over its effectiveness.
-
Cipla Set To Undercut Rivals With Generic Remdesivir: Sources
Indian drugmaker Cipla Ltd has priced its generic version of Remdesivir, Cipremi, at 4,000 rupees ($53.34) per 100 mg vial, according to several sources, making it among the lowest priced versions of the COVID-19 treatment available so far globally.
-
These Two Stocks To Be Added Into Sensex
Drugmakers Lupin Ltd and Cipla Ltd will make way for the two banks, according to a statement from Asia Index Pvt Ltd.
